Rothenbacher D, Hoffmann MM, Breitling LP, et al. Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care[J]. BMC Cardiovasc Disord, 2013 ,27;13:61.
[4]
Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in theTRITON-TIMI 38 trial: a pharmacogenetic analysis[J]. Lancet,2010,16:376(9749):1312-1319.
[5]
Sanford JC, Guo Y, Sadee W, et al. Regulatory polymorphisms in CYP2C19 affecting hepatic expression[J]. Drug Metabol Drug Interact, 2013,28(1):23-30.
[6]
Simon T,Verstuyft C,Mary-Krause M,et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4 ):363-375.
